Okomera
Okomera is revolutionizing drug discovery with its Ocentra platform, an automated organoid screening engine. This technology allows for high-throughput testing of up to 800 conditions on 1000 microtumors per run, utilizing only 50 cells to generate an organoid. Key features include miniaturization, multiplexing of over 100 conditions, co-culture capabilities with up to 3 cell types, and an end-to-end AI analysis platform. Okomera aims to modernize preclinical studies, improving their predictability and enabling diverse use cases like CRISPR, T-cell potency, and drug screening. Their proprietary technology offers a significantly faster turnaround time, achieving results six times faster than competitors with no lab operator needed. The company has showcased its advancements at conferences like SLAS and published in journals such as Cell Reports and Nature Communications, highlighting their contribution to personalized medicine.
Okomera
Okomera is revolutionizing drug discovery with its Ocentra platform, an automated organoid screening engine. This technology allows for high-throughput testing of up to 800 conditions on 1000 microtumors per run, utilizing only 50 cells to generate an organoid. Key features include miniaturization, multiplexing of over 100 conditions, co-culture capabilities with up to 3 cell types, and an end-to-end AI analysis platform. Okomera aims to modernize preclinical studies, improving their predictability and enabling diverse use cases like CRISPR, T-cell potency, and drug screening. Their proprietary technology offers a significantly faster turnaround time, achieving results six times faster than competitors with no lab operator needed. The company has showcased its advancements at conferences like SLAS and published in journals such as Cell Reports and Nature Communications, highlighting their contribution to personalized medicine.
TL;DR
Core product: Ocentra — an automated, miniaturized organoid/microtumor screening engine for high-throughput drug discovery
Throughput & features: Up to ~1,000 microtumors per run, multiplexing 100+ conditions, co-culture of up to 3 cell types, AI-driven analysis
Funding (recent): Announced €10.2M raise (Dec 21, 2023); total funding reported as 12,785,720 USD
Founding / HQ: Founded 2020; HQ in Greater Paris (Montreuil) with an address in Sunnyvale, CA
Investors include Resonance (lead on Seed), Polytechnique Ventures, Berkeley SkyDeck Fund, Bpifrance, Agoranov, Jacques Lewiner, Irwan Bello